OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

Liam G Heaney; Andrew Menzies-Gow; Mark Gurnell; Jonathan  Corren; Elisabeth H Bel; Jorge F Maspero; Timothy  Harrison; David Jackson; David Price; Njira Lugogo; James  Kreindler; Annie Burden; Alex  de Giorgio-Miller; Kelly  Padilla; Ubaldo J.  Martin; Esther Garcia Gil

doi:10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355

OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

Liam G Heaney, Andrew Menzies-Gow, Mark Gurnell, Jonathan Corren, Elisabeth H Bel, Jorge F Maspero, Timothy Harrison, David Jackson, David Price, Njira Lugogo, James Kreindler, Annie Burden, Alex de Giorgio-Miller, Kelly Padilla, Ubaldo J. Martin, Esther Garcia Gil

Research output: Contribution to journal › Abstract › peer-review

18 Downloads (Pure)

Abstract

Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function. I

Original language	English
Article number	A1355
Number of pages	1
Journal	American Journal of Respiratory and Critical Care Medicine
Volume	203
Early online date	19 May 2021
DOIs	https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355
Publication status	Published - 2021
Event	ATS International Conference Committee: ATS 2021 - Virtual event Duration: 14 May 2021 → 19 May 2021 https://conference.thoracic.org/

Access to Document

10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355Licence: Unspecified

Heany_et_al_ATS21_OCSReductionAccording_AAM
Originally Published in: L.G. Heaney 13, A. Menzies-Gow 14, M. Gurnell 16, J. Corren 8, E. Bel 1, J. Maspero 9, T. Harrison 11, D. Jackson 10, D. Price 12, N.L. Lugogo 15, J.L. Kreindler 4, A. Burden 2, A. De Giorgio-Miller 7, K. Padilla 5, U.J. Martin 6, E. Garcia Gil. OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study.ATS JOurnal, 2021;203,A1355. DOI:https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355Copyright © 2021 by the American Thoracic Society The final publication is available at
Accepted author manuscript, 161 KBLicence: Other

Cite this

Heaney, L. G., Menzies-Gow, A., Gurnell, M., Corren, J., Bel, E. H., Maspero, J. F., Harrison, T., Jackson, D., Price, D., Lugogo, N., Kreindler, J., Burden, A., de Giorgio-Miller, A., Padilla, K., Martin, U. J., & Gil, E. G. (2021). OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study. American Journal of Respiratory and Critical Care Medicine, 203, [A1355]. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355

Heaney, LG, Menzies-Gow, A, Gurnell, M, Corren, J, Bel, EH, Maspero, JF, Harrison, T, Jackson, D, Price, D, Lugogo, N, Kreindler, J, Burden, A, de Giorgio-Miller, A, Padilla, K, Martin, UJ & Gil, EG 2021, 'OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study', American Journal of Respiratory and Critical Care Medicine, vol. 203, A1355. https://doi.org/10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355

@article{76fad59ed92c4d88b26d54c7eadfc697,

title = "OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study",

abstract = " Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function. I",

author = "Heaney, {Liam G} and Andrew Menzies-Gow and Mark Gurnell and Jonathan Corren and Bel, {Elisabeth H} and Maspero, {Jorge F} and Timothy Harrison and David Jackson and David Price and Njira Lugogo and James Kreindler and Annie Burden and {de Giorgio-Miller}, Alex and Kelly Padilla and Martin, {Ubaldo J.} and Gil, {Esther Garcia}",

year = "2021",

doi = "10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355",

language = "English",

volume = "203",

journal = "American Journal of Respiratory and Critical Care Medicine",

issn = "1073-449X",

publisher = "American Thoracic Society - AJRCCM",

note = "ATS International Conference Committee : ATS 2021 ; Conference date: 14-05-2021 Through 19-05-2021",

url = "https://conference.thoracic.org/",

}

TY - JOUR

T1 - OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

AU - Heaney, Liam G

AU - Menzies-Gow, Andrew

AU - Gurnell, Mark

AU - Corren, Jonathan

AU - Bel, Elisabeth H

AU - Maspero, Jorge F

AU - Harrison, Timothy

AU - Jackson, David

AU - Price, David

AU - Lugogo, Njira

AU - Kreindler, James

AU - Burden, Annie

AU - de Giorgio-Miller, Alex

AU - Padilla, Kelly

AU - Martin, Ubaldo J.

AU - Gil, Esther Garcia

PY - 2021

Y1 - 2021

N2 - Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function. I

AB - Severe asthma is frequently associated with comorbidities. Nasal polyps (NP), in particular, indicate an eosinophilic phenotype and have been shown to predict an enhanced response to benralizumab in terms of asthma exacerbations and lung function. I

U2 - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355

DO - 10.1164/ajrccm-conference.2021.203.1_MeetingAbstracts.A1355

M3 - Abstract

VL - 203

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

M1 - A1355

T2 - ATS International Conference Committee

Y2 - 14 May 2021 through 19 May 2021

ER -

OCS Reduction According to the Presence of Nasal Polyps or Atopic Status in the PONENTE Study

Abstract

Access to Document

Fingerprint

Cite this